XENT تصريحات هيئة الأوراق المالية والبورصات - Intersect ENT Inc- التقرير السنوي، بيان التوكيل، نشرة الإصدار

الإحصائيات الأساسية

LEI	549300SWZUVLSFMOXR50
CIK	1271214

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Intersect ENT Inc

SEC Filings (Chronological Order)

توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.

February 10, 2023	SC 13G/A	XENT / Intersect ENT Inc / Versor Investments LP Passive Investment SC 13G/A 1 versor-xent123122a4.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* INTERSECT ENT, INC. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 46071F103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the a
September 12, 2022	RW WD	Intersect ENT, Inc. 1555 Adams Drive Menlo Park, California 94025 Intersect ENT, Inc. 1555 Adams Drive Menlo Park, California 94025 September 12, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Intersect ENT, Inc. Registration Statement on Form S-3ASR Filed May 13, 2022 No. 333-237805 Withdrawal of Registration Withdrawal Request Previously Made on Form RW Ladies and Gentlemen: In
September 12, 2022	POSASR	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-237805 THE SECURITIES ACT OF 1933 Intersect ENT, INC. (Exact name of registrant as specified in its char POSASR 1 d341739dposasr.htm POSASR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-237805 UNDER THE SECURITIES ACT OF 1933 Intersect ENT, INC. (Exact name of registrant as specified in its charter) Delaware 20-0280837 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Iden
May 23, 2022	15-12B	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 15-12B 1 d344652d1512b.htm 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-36545 Intersect ENT, Inc. (Exact name of
May 19, 2022	S-8 POS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-263368 FORM S-8 REGISTRATION STATEMENT NO. 333-254034 FORM S-8 REGISTRATION STATEMENT NO. 333-236706 FORM S S-8 POS 1 brhc10037429s8pos.htm S-8 POS Registration No. 333-263368 Registration No. 333-254034 Registration No. 333-236706 Registration No. 333-229956 Registration No. 333-226591 Registration No. 333-223307 Registration No. 333-216319 Registration No. 333-209713 Registration No. 333-202670 Registration No. 333-197885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Eff
May 13, 2022	EX-3.2	AMENDED AND RESTATED BYLAWS INTERSECT ENT, INC. ARTICLE I Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF INTERSECT ENT, INC. ARTICLE I Offices SECTION 1. REGISTERED OFFICE. The registered office of the corporation shall be established and maintained at the office of the Corporation Service Company, 241 Little Falls Drive, Wilmington, New Castle County, Delaware 19808, and said corporation shall be the registered agent of this corporation in charge thereof. S
May 13, 2022	S-8 POS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-263368 FORM S-8 REGISTRATION STATEMENT NO. 333-254034 FORM S-8 REGISTRATION STATEMENT NO. 333-236706 FORM S S-8 POS 1 brhc10037429s8pos.htm S-8 POS Registration No. 333-263368 Registration No. 333-254034 Registration No. 333-236706 Registration No. 333-229956 Registration No. 333-226591 Registration No. 333-223307 Registration No. 333-216319 Registration No. 333-209713 Registration No. 333-202670 Registration No. 333-197885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Eff
May 13, 2022	S-8 POS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-263368 FORM S-8 REGISTRATION STATEMENT NO. 333-254034 FORM S-8 REGISTRATION STATEMENT NO. 333-236706 FORM S S-8 POS 1 brhc10037429s8pos.htm S-8 POS Registration No. 333-263368 Registration No. 333-254034 Registration No. 333-236706 Registration No. 333-229956 Registration No. 333-226591 Registration No. 333-223307 Registration No. 333-216319 Registration No. 333-209713 Registration No. 333-202670 Registration No. 333-197885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Eff
May 13, 2022	S-8 POS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-263368 FORM S-8 REGISTRATION STATEMENT NO. 333-254034 FORM S-8 REGISTRATION STATEMENT NO. 333-236706 FORM S S-8 POS 1 brhc10037429s8pos.htm S-8 POS Registration No. 333-263368 Registration No. 333-254034 Registration No. 333-236706 Registration No. 333-229956 Registration No. 333-226591 Registration No. 333-223307 Registration No. 333-216319 Registration No. 333-209713 Registration No. 333-202670 Registration No. 333-197885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Eff
May 13, 2022	S-8 POS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-263368 FORM S-8 REGISTRATION STATEMENT NO. 333-254034 FORM S-8 REGISTRATION STATEMENT NO. 333-236706 FORM S S-8 POS 1 brhc10037429s8pos.htm S-8 POS Registration No. 333-263368 Registration No. 333-254034 Registration No. 333-236706 Registration No. 333-229956 Registration No. 333-226591 Registration No. 333-223307 Registration No. 333-216319 Registration No. 333-209713 Registration No. 333-202670 Registration No. 333-197885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Eff
May 13, 2022	RW	Intersect ENT, Inc. 1555 Adams Drive Menlo Park, California 94025 RW 1 brhc10037435rw.htm RW Intersect ENT, Inc. 1555 Adams Drive Menlo Park, California 94025 May 13, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C 20549 Application for Withdrawal of Registration Statement on Form S-3ASR (File No. 333-237805) Ladies and Gentlemen: Intersect ENT, Inc., a Delaware corporation (the “Company”), her
May 13, 2022	S-8 POS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-263368 FORM S-8 REGISTRATION STATEMENT NO. 333-254034 FORM S-8 REGISTRATION STATEMENT NO. 333-236706 FORM S S-8 POS 1 brhc10037429s8pos.htm S-8 POS Registration No. 333-263368 Registration No. 333-254034 Registration No. 333-236706 Registration No. 333-229956 Registration No. 333-226591 Registration No. 333-223307 Registration No. 333-216319 Registration No. 333-209713 Registration No. 333-202670 Registration No. 333-197885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Eff
May 13, 2022	S-8 POS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-263368 FORM S-8 REGISTRATION STATEMENT NO. 333-254034 FORM S-8 REGISTRATION STATEMENT NO. 333-236706 FORM S Registration No. 333-263368 Registration No. 333-254034 Registration No. 333-236706 Registration No. 333-229956 Registration No. 333-226591 Registration No. 333-223307 Registration No. 333-216319 Registration No. 333-209713 Registration No. 333-202670 Registration No. 333-197885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGIS
May 13, 2022	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 May 13, 2022 Date of Report (Date of earliest event reported) Intersect ENT, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36545 20-0280837 (State or Other Jurisdiction of Incorporation) (Commission File Nu
May 13, 2022	EX-99.1	Medtronic completes acquisition of Intersect ENT Acquisition adds innovative bioabsorbable steroid-eluting sinus implants to ENT portfolio Exhibit 99.1 NEWS RELEASE Contacts: Brett Cromwell Ryan Weispfenning Public Relations Investor Relations +1-617-899-7091 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic completes acquisition of Intersect ENT Acquisition adds innovative bioabsorbable steroid-eluting sinus implants to ENT portfolio DUBLIN and MENLO PARK, Calif. ? May 13, 2022 ? Medtronic plc (NYSE:MDT), a global leader in healthcare
May 13, 2022	S-8 POS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-263368 FORM S-8 REGISTRATION STATEMENT NO. 333-254034 FORM S-8 REGISTRATION STATEMENT NO. 333-236706 FORM S Registration No. 333-263368 Registration No. 333-254034 Registration No. 333-236706 Registration No. 333-229956 Registration No. 333-226591 Registration No. 333-223307 Registration No. 333-216319 Registration No. 333-209713 Registration No. 333-202670 Registration No. 333-197885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGIS
May 13, 2022	S-8 POS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-263368 FORM S-8 REGISTRATION STATEMENT NO. 333-254034 FORM S-8 REGISTRATION STATEMENT NO. 333-236706 FORM S S-8 POS 1 brhc10037429s8pos.htm S-8 POS Registration No. 333-263368 Registration No. 333-254034 Registration No. 333-236706 Registration No. 333-229956 Registration No. 333-226591 Registration No. 333-223307 Registration No. 333-216319 Registration No. 333-209713 Registration No. 333-202670 Registration No. 333-197885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Eff
May 13, 2022	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION INTERSECT ENT, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTERSECT ENT, INC. 1. The name of the corporation shall be Intersect ENT, Inc. (the ?Corporation?). 2. The address of its registered office in the State of Delaware is: Corporation Service Company, 251 Little Falls Drive, Wilmington, New Castle County, Delaware 19808. The name of its registered agent at such address is Corporation S
May 13, 2022	POS AM	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-3 REGISTRATION STATEMENT NO. 333-238963 UNDER THE SECURITIES ACT OF 1933 Intersect ENT, Inc. (Exact name of registrant as specified in its c POS AM 1 brhc10037408s-3posam.htm S-3 POS AM Registration No. 333-238963 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-238963 UNDER THE SECURITIES ACT OF 1933 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 20-0280837 (State or other jurisdiction of incorporation
May 13, 2022	S-8 POS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-263368 FORM S-8 REGISTRATION STATEMENT NO. 333-254034 FORM S-8 REGISTRATION STATEMENT NO. 333-236706 FORM S Registration No. 333-263368 Registration No. 333-254034 Registration No. 333-236706 Registration No. 333-229956 Registration No. 333-226591 Registration No. 333-223307 Registration No. 333-216319 Registration No. 333-209713 Registration No. 333-202670 Registration No. 333-197885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGIS
May 13, 2022	S-8 POS	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 FORM S-8 REGISTRATION STATEMENT NO. 333-263368 FORM S-8 REGISTRATION STATEMENT NO. 333-254034 FORM S-8 REGISTRATION STATEMENT NO. 333-236706 FORM S Registration No. 333-263368 Registration No. 333-254034 Registration No. 333-236706 Registration No. 333-229956 Registration No. 333-226591 Registration No. 333-223307 Registration No. 333-216319 Registration No. 333-209713 Registration No. 333-202670 Registration No. 333-197885 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-8 REGIS
May 9, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2022 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File Nu
May 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36545 INTERSECT ENT, INC. (Exac
April 29, 2022	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No.1) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Amendment No.1) (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commissio
April 18, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2022 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
April 18, 2022	EX-10.1	Amendment No. 1 to Facility Agreement, dated as of April 15, 2022, by and among Intersect ENT, Inc., certain of Intersect ENT, Inc.’s subsidiaries from time to time party thereto as guarantors and Medtronic, Inc. Exhibit 10.1 EXECUTED AMENDMENT NO. 1 TO FACILITY AGREEMENT THIS AMENDMENT NO. 1 TO FACILITY AGREEMENT, dated as of April 15, 2022 (this ?Amendment?), is made by and between Intersect ENT, Inc., a Delaware corporation (the ?Borrower?) and Medtronic, Inc., a Minnesota corporation (the ?Lender?). WHEREAS, the Borrower and the Lender are party to that certain Facility Agreement, dated as of September
March 23, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
March 8, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-
March 8, 2022	S-8	As filed with the Securities and Exchange Commission on March 8, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 Intersect ENT, Inc. (Exact S-8 1 xent-20220308xsx8.htm S-8 As filed with the Securities and Exchange Commission on March 8, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intersect ENT, Inc. (Exact name of Registrant as specified in its charter) Delaware 20-0280837 (State or other jurisdiction of Incorporatio
March 8, 2022	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 CALCULATION OF FILING FEE TABLES Form S-8 Intersect ENT, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Share(2) Proposed Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.001 per share, 2014 Equity Incentive Plan Ot
February 23, 2022	SC 13G/A	XENT / Intersect ENT Inc / Versor Investments LP Passive Investment SC 13G/A 1 versor-xent021422a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* INTERSECT ENT, INC. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 46071F103 (CUSIP Number) February 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the a
February 17, 2022	SC 13G/A	XENT / Intersect ENT Inc / Versor Investments LP Passive Investment SC 13G/A 1 versor-xent020722a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* INTERSECT ENT, INC. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 46071F103 (CUSIP Number) February 7, 2022 (Date of Event Which Requires Filing of this Statement) Check the ap
February 14, 2022	SC 13G/A	XENT / Intersect ENT Inc / First Light Asset Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* (Amendment No. 2) Intersect ENT Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 46071F103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t
February 10, 2022	SC 13G/A	XENT / Intersect ENT Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01181-intersectentinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Intersect ENT Inc. Title of Class of Securities: Common Stock CUSIP Number: 46071F103 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate
February 8, 2022	SC 13G/A	XENT / Intersect ENT Inc / Versor Investments LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
November 2, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fi
November 2, 2021	EX-99.1	Intersect ENT Reports Third Quarter 2021 Financial Results Exhibit 99.1 Intersect ENT Reports Third Quarter 2021 Financial Results MENLO PARK, Calif. ? November 2, 2021 ? Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (?ENT?) medical technology leader dedicated to transforming patient care, today reported financial results for the third quarter ended September 30, 2021. Total revenue was $24.4 million for the third quarter of 2021, up 7
November 2, 2021	EX-10.1	Amendment to Offer Letter by and between the registrant and Thomas A. West, effective August 14, 2021 Exhibit 10.1 August 13, 2021 Thomas West VIA EMAIL/DOCUSIGN Dear Thomas: As you know, you are a party to an employment agreement with Intersect ENT, Inc. (the ?Company?) dated June 24, 2019 (the ?Agreement?). The Company is hereby amending the Agreement on the terms set forth below. Capitalized terms not defined herein shall have the meaning set forth in the Agreement. The first sentence of the de
November 2, 2021	EX-10.2	Amendment to Offer Letter by and between the registrant and Richard A. Meier, effective August 13, 2021 Exhibit 10.2 August 13, 2021 Richard A. Meier VIA EMAIL/DOCUSIGN Dear Randy: As you know, you are a party to an employment agreement with Intersect ENT, Inc. (the ?Company?) dated November 26, 2019 (the ?Agreement?). The Company is hereby amending the Agreement on the terms set forth below. Capitalized terms not defined herein shall have the meaning set forth in the Agreement. If it shall be deter
November 2, 2021	EX-10.3	Amendment to Offer Letter by and between the registrant and Reyna M. Fernandez, effective August 16, 2021 Exhibit 10.3 August 13, 2021 Reyna Fernandez VIA EMAIL/DOCUSIGN Dear Reyna: As you know, you are a party to an employment agreement with Intersect ENT, Inc. (the ?Company?) dated November 13, 2020 (the ?Agreement?). The Company is hereby amending the Agreement on the terms set forth below. Capitalized terms not defined herein shall have the meaning set forth in the Agreement. If it shall be determ
November 2, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36545 INTERSECT ENT, INC. (
November 2, 2021	EX-10.5	Letter from the registrant to Thomas A. West regarding acceleration of certain performance-based awards, dated as of September 7, 2021 Exhibit 10.5 Date: September 7, 2021 To: Thomas A. West Subject: Equity Acceleration We are pleased to share with you that the Board of Directors of Intersect ENT, Inc. (the ?Company?) have granted you certain equity acceleration benefits, as described below. This letter will serve as an amendment to certain vesting acceleration provisions included in your performance-based vesting equity awards,
November 2, 2021	EX-10.6	Letter from the registrant to Richard A. Meier regarding acceleration of certain performance-based awards, dated as of September 7, 2021 Exhibit 10.6 Date: September 7, 2021 To: Richard A. Meier Subject: Equity Acceleration We are pleased to share with you that the Board of Directors of Intersect ENT, Inc. (the ?Company?) have granted you certain equity acceleration benefits, as described below. This letter will serve as an amendment to certain vesting acceleration provisions included in your performance-based vesting equity award,
November 2, 2021	EX-10.4	Amendment to Offer Letter by and between the registrant and Patrick A. Broderick, effective August 14, 2021 Exhibit 10.4 August 13, 2021 Patrick Broderick VIA EMAIL/DOCUSIGN Dear Patrick: As you know, you are a party to an employment agreement with Intersect ENT, Inc. (the ?Company?) dated November 12, 2020 (the ?Agreement?). The Company is hereby amending the Agreement on the terms set forth below. Capitalized terms not defined herein shall have the meaning set forth in the Agreement. If it shall be de
October 20, 2021	SC 13G	XENT / Intersect ENT Inc / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INTERSECT ENT, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 46071F103 (CUSIP Number) OCTOBER 11, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which
October 8, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fil
September 30, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame DEFA14A 1 xent-20210930xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate
September 27, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission
September 27, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 Intersect ENT, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission
September 27, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission
September 27, 2021	EX-10.1	Facility Agreement, dated as of September 25, 2021, by and among Intersect ENT, Inc., certain of Intersect ENT, Inc.'s subsidiaries from time to time party thereto as guarantors and Medtronic, Inc. Exhibit 10.1 Execution Version THIS INSTRUMENT, AS WELL AS THE INDEBTEDNESS, RIGHTS AND OBLIGATIONS EVIDENCED HEREBY, ARE AND SHALL AT ALL TIMES BE AND REMAIN SUBORDINATED IN RIGHT AND TIME OF PAYMENT TO THE EXTENT AND IN THE MANNER SET FORTH IN THAT CERTAIN SUBORDINATION AGREEMENT (AS AMENDED, SUPPLEMENTED, RESTATED, OR OTHERWISE MODIFIED FROM TIME TO TIME IN ACCORDANCE WITH THE TERMS THEREOF, TH
September 7, 2021	DEFM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? Check the appropriate box: ?? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
August 27, 2021	PREM14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? ? ? Filed by a party other than the Registrant ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
August 19, 2021	SC 13D	XENT / Intersect ENT Inc / Magnetar Financial LLC - SC 13D Activist Investment SC 13D 1 tm2125412dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Intersect ENT, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 46071F103 (CUSIP Number of Class of Securities) Alec N. Litowitz Magnetar Capital LLC 1603 Orrington Ave. Evanston, Ill
August 19, 2021	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k), as promulgated under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them a Statement on Schedule 13D (including amendments thereto) with regard to the common stock of Intersect ENT, Inc., and further agree that this Joint Filing Agreement be included as an
August 17, 2021	SC 13G	XENT / Intersect ENT Inc / Versor Investments LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
August 16, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
August 16, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
August 13, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
August 10, 2021	EX-2.1	AGREEMENT AND PLAN OF MERGER MEDTRONIC, INC. PROJECT KRAKEN MERGER SUB, INC. INTERSECT ENT, INC. Dated as of August 6, 2021 TABLE OF CONTENTS Page ARTICLE I THE MERGER 1 Section 1.1 The Merger 1 Section 1.2 Effective Time 3 ARTICLE II CONVERSION OF S Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AMONG MEDTRONIC, INC. PROJECT KRAKEN MERGER SUB, INC. AND INTERSECT ENT, INC. Dated as of August 6, 2021 TABLE OF CONTENTS Page ARTICLE I THE MERGER 1 Section 1.1 The Merger 1 Section 1.2 Effective Time 3 ARTICLE II CONVERSION OF SHARES 3 Section 2.1 Conversion of Securities 3 Section 2.2 Exchange of Certificates and Book Entry Shares 4 Section 2.3 Shares o
August 10, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2021 Intersect ENT, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
August 10, 2021	EX-2.1	Agreement and Plan of Merger, dated as of August 6, 2021, by and among Medtronic, Inc., a Minnesota corporation, Project Kraken Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Medtronic, Inc., and Intersect ENT, Inc., a Delaware corporation. Exhibit 2.1 AGREEMENT AND PLAN OF MERGER AMONG MEDTRONIC, INC. PROJECT KRAKEN MERGER SUB, INC. AND INTERSECT ENT, INC. Dated as of August 6, 2021 TABLE OF CONTENTS Page ARTICLE I THE MERGER 1 Section 1.1 The Merger 1 Section 1.2 Effective Time 3 ARTICLE II CONVERSION OF SHARES 3 Section 2.1 Conversion of Securities 3 Section 2.2 Exchange of Certificates and Book Entry Shares 4 Section 2.3 Shares o
August 10, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 5, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
August 9, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2021 Intersect ENT, Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
August 6, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36545 INTERSECT ENT, INC. (Exact
August 6, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
August 6, 2021	EX-99.1	MEDTRONIC TO ACQUIRE INTERSECT ENT Acquisition to Add Innovative Bioabsorbable Drug Release Platform to Chronic Rhinosinusitis Portfolio Exhibit 99.1 NEWS RELEASE Medtronic Contacts: John Jordan Ryan Weispfenning Public Relations Investor Relations +1-508-452-4891 +1-763-505-4626 Intersect ENT Contacts: Randy Meier Executive Vice President and CFO +1-650-641-2105 [email protected] FOR IMMEDIATE RELEASE MEDTRONIC TO ACQUIRE INTERSECT ENT Acquisition to Add Innovative Bioabsorbable Drug Release Platform to Chronic Rhinosinusitis Po
August 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
August 6, 2021	EX-99.1	Intersect ENT Reports Second Quarter 2021 Financial Results Exhibit 99.1 Intersect ENT Reports Second Quarter 2021 Financial Results MENLO PARK, Calif. ? August 6, 2021 ? Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (?ENT?) medical technology leader dedicated to transforming patient care, today reported financial results for the second quarter ended June 30, 2021. Second Quarter 2021 Overview ?Entered into a definitive agreement with M
July 22, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
July 22, 2021	EX-99.1	Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan Exhibit 99.1 Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan MENLO PARK, Calif. ? July 22, 2021 ? Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (?ENT?) medical technology leader dedicated to transforming patient care, today announced preliminary second quarter 2021 revenue and provided a business update. Second Quarter
July 22, 2021	EX-10.1	Facility Agreement, dated as of July 22, 2021, by and among Intersect ENT, Inc., certain of Intersect ENT's subsidiaries from time to time party thereto as guarantors and Deerfield Partners, L.P. FACILITY AGREEMENT dated as of July 22, 2021 by and among INTERSECT ENT, INC., as the Borrower, the other Loan Parties party hereto from time to time, the Lenders and DEERFIELD PARTNERS, L.P., as agent for itself and the Secured Parties Table of Contents ARTICLE 1 DEFINITIONS 1 Section 1.1 General Definitions 1 Section 1.2 Interpretation 25 Section 1.3 Business Day Adjustment 26 Section 1.4 Loan R
June 7, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File N
June 4, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File N
May 18, 2021	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File N
May 10, 2021	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36545 INTERSECT ENT, INC. (Exac
May 10, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File N
May 10, 2021	EX-99.1	Intersect ENT Reports First Quarter 2021 Financial Results - Increases 2021 Revenue Guidance to $117 Million to $121 Million - Exhibit 99.1 Intersect ENT Reports First Quarter 2021 Financial Results - Increases 2021 Revenue Guidance to $117 Million to $121 Million - MENLO PARK, Calif. ? May 10, 2021 ? Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (?ENT?) medical technology leader dedicated to transforming patient care, today reported financial results for the first quarter ended March 31, 2021. First Q
April 20, 2021	DEF 14A	- DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14
April 20, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 5, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
March 11, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
March 9, 2021	EX-10.14	Offer Letter by and between the registrant and Patrick A. Broderick, dated as of November 12, 2020 Exhibit 10.14 November 12, 2020 Patrick Broderick Re: Employment Terms Dear Patrick: Intersect ENT, Inc. (the ?Company?) is pleased to offer you the position of Executive Vice President, General Counsel and Corporate Secretary on the following terms. You will be responsible for all aspects of the Company?s legal, intellectual property and compliance functions. You will report directly to me, as th
March 9, 2021	EX-10.16	Amended Non-Employee Director Compensation Policy Exhibit 10.16 NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Our non-employee directors receive an annual retainer of $45,000. Our lead director receives an additional retainer of $30,000. In addition, all non-employee directors who serve on one or more committees will receive the following annual committee fees: Committee Chair Member Audit $ 20,000 $ 10,000 Compensation 15,000 7,500 Nominating and Co
March 9, 2021	EX-10.15	Offer Letter by and between the registrant and Reyna M. Fernandez, dated as of November 13, 2020 Exhibit 10.15 November 13, 2020 Reyna M. Fernandez Re: Employment Terms Dear Reyna: Intersect ENT, Inc. (the ?Company?) is pleased to offer you the position of Chief Human Resources Officer on the following terms You will be responsible for all aspects of the Company?s human resources functions. You will report directly to me, as the Company's CEO, and this role is based in our offices located in
March 9, 2021	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-
March 9, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
March 9, 2021	EX-99.1	Intersect ENT Reports Fourth Quarter and Full Year 2020 Financial Results Exhibit 99.1 Intersect ENT Reports Fourth Quarter and Full Year 2020 Financial Results MENLO PARK, Calif. — March 9, 2021 — Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the fourth quarter and full year ended December 31, 2020. Fourth Quarter 2020 Overview •Revenue tot
March 9, 2021	EX-4.2	Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 9, 2021, Intersect ENT, Inc. has one class of Common Stock securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). Description of Common Stock The following description of our Common Stock is a summary an
March 9, 2021	S-8	- S-8 As filed with the Securities and Exchange Commission on March 9, 2021 Registration No.
February 18, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission F
February 12, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3) * Inter SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
February 12, 2021	SC 13G/A	SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 3)* Intersec SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 3)* Intersect ENT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Fili
February 12, 2021	EX-99.1	JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Intersect ENT Inc. Title of Class of Securities: Common Stock CUSIP Number: 46071F103 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒
January 12, 2021	EX-99.1	Intersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020 - Preliminary Unaudited Fourth Quarter 2020 Revenue Expected to be $27.7 to $28.1 Million - EX-99.1 2 xent-20210112xex991.htm EX-99.1 Exhibit 99.1 Intersect ENT Announces Preliminary Revenue for Fourth Quarter of 2020 - Preliminary Unaudited Fourth Quarter 2020 Revenue Expected to be $27.7 to $28.1 Million - MENLO PARK, Calif. — January 12, 2021 — Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, to
January 12, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fi
December 23, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission F
December 23, 2020	EX-10.1	Third Amendment to Lease by and between the registrant, Menlo Prepi I, LLC, and TPI Investors 9, LLC, dated as of December 22, 2020 Exhibit 10.1 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (“Amendment”) dated as of December 22, 2020 (the “Execution Date”) is made and entered into by and between MENLO PREPI I, LLC, a Delaware limited liability company, and TPI INVESTORS 9, LLC, a California limited liability company (collectively, “Lessor”), and INTERSECT ENT, INC., a Delaware corporation (“Lessee”), with respect to
November 18, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission F
November 2, 2020	EX-99.1	Intersect ENT Reports Third Quarter 2020 Financial Results Exhibit 99.1 Intersect ENT Reports Third Quarter 2020 Financial Results MENLO PARK, Calif. — November 2, 2020 — Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the third quarter ended September 30, 2020. Third Quarter 2020 Overview •Revenue of $22.7 million in the third quarter of 2020,
November 2, 2020	EX-10.1	Fiagon AG Medical Technologies Sale and Purchase Agreement, dated as of October 2, 2020 Exhibit 10.1 SALE AND PURCHASE AGREEMENT relating to the acquisition of all shares in Fiagon AG Medical Technologies TABLE OF CONTENTS 1. SALE AND PURCHASE OF THE SHARES 11 1.1 Defined Terms 11 1.2 Approval of Transaction 11 1.3 The Company 11 1.4 Registered Share Capital 11 1.5 Subsidiaries 12 1.6 Sale and Transfer of the Shares 12 1.7 Purchase Price for the Shares 12 1.8 Payment of the Purchase
November 2, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36545 INTERSECT ENT, INC. (
November 2, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fi
October 15, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fi
October 15, 2020	EX-99.1	Intersect ENT Announces Preliminary Revenue for Third Quarter of 2020 - Preliminary Third Quarter 2020 Revenue Expected to be $22.4 to $22.8 Million - Exhibit 99.1 Intersect ENT Announces Preliminary Revenue for Third Quarter of 2020 - Preliminary Third Quarter 2020 Revenue Expected to be $22.4 to $22.8 Million - MENLO PARK, Calif. — October 15, 2020 — Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced preliminary third quarter 2020 revenue and provided a bus
October 2, 2020	8-K	Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fil
September 18, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission
September 15, 2020	8-K	Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 15, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission
August 5, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36545 INTERSECT ENT, INC. (Exact
August 4, 2020	EX-99.1	Intersect ENT Reports Second Quarter 2020 Financial Results EX-99.1 Exhibit 99.1 Intersect ENT Reports Second Quarter 2020 Financial Results MENLO PARK, Calif. — August 4, 2020 — Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the second quarter ended June 30, 2020. Second Quarter 2020 Overview • Revenue of $9.8 million in the second quarter of 2
August 4, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
June 18, 2020	424B3	Intersect ENT, Inc. 6,309,459 Shares Common Stock 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-238963 PROSPECTUS Intersect ENT, Inc. 6,309,459 Shares Common Stock This prospectus relates to an aggregate of up to 6,309,459 shares of our common stock, par value $0.001 per share, which may be offered for sale from time to time by the selling stockholder named herein. We will not receive any of the proceeds from any s
June 15, 2020	CORRESP	- Acceleration Request INTERSECT ENT, INC. 1555 Adams Drive Menlo Park, CA 94025 June 15, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ada D. Sarmento RE: Intersect ENT, Inc. Registration Statement on Form S-3 File No. 333-238963 Acceleration Request Requested Date: June 17, 2020 Requested Time: 4:00 p
June 15, 2020	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTERSECT ENT, INC. INTERSECT ENT, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “corporation”), hereby certifies that: FIRST: The name of the corporation is INTERSECT ENT, INC. The corporation was originally incorporated
June 15, 2020	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File N
June 5, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File N
June 5, 2020	S-3	- S-3 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 5, 2020 Registration No.
May 11, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36545 INTERSECT ENT, INC. (Exac
May 11, 2020	EX-99.1	Intersect ENT Reports First Quarter 2020 Results EX-99.1 Exhibit 99.1 Intersect ENT Reports First Quarter 2020 Results MENLO PARK, Calif. — May 11, 2020 — Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the first quarter ended March 31, 2020. First Quarter 2020 Overview • Revenue of $19.8 million in the first quarter of 2020, compared
May 11, 2020	EX-10.2	Registration Rights Agreement, dated as of May 11, 2020, by and between Intersect ENT, Inc. and Deerfield Partners, L.P. EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of May 11, 2020, by and between Intersect ENT, Inc., a Delaware corporation (the “Company”), and Deerfield Partners, L.P. (the “Lender”). WHEREAS: A. In connection with the Facility Agreement, dated as of the date hereof, by and among the Company, the Lender, the other Loan Parties (as def
May 11, 2020	EX-10.2	Amended Non-Employee Director Compensation Policy EX-10.2 Exhibit 10.2 AMENDED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Our non-employee directors receive an annual retainer of $40,000. Our Board Chairman receives an additional retainer of $40,000. In addition, all non-employee directors who serve on one or more committees will receive the following annual committee fees: Committee Chair Member Audit $ 20,000 $ 10,000 Compensation 15,000 7,500 N
May 11, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File N
May 11, 2020	EX-10.1	Supply Agreement between the registrant and Hovione Inter AG., dated as of January 20, 2020 EX-10.1 Exhibit 10.1 [*] Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (this “Agreement”) is made this, 20th day of January, 2020 (the “Effective Date”), by and between HOVIONE INTER AG, together with its subsidiarie
May 11, 2020	EX-10.1	Facility Agreement, dated as of May 11, 2020, by and among Intersect ENT, Inc., certain of Intersect ENT, Inc’s subsidiaries from time to time party thereto as guarantors and Deerfield Partners, L.P. EX-10.1 Exhibit 10.1 Execution Version FACILITY AGREEMENT dated as of May 11, 2020 by and among INTERSECT ENT, INC., as the Borrower, the other Loan Parties party hereto from time to time, the Lenders and DEERFIELD PARTNERS, L.P., as agent for itself and the Lender Parties Table of Contents ARTICLE 1 DEFINITIONS 1 Section 1.1 General Definitions 1 Section 1.2 Interpretation 21 Section 1.3 Business
May 11, 2020	EX-3.1	Certificate of Designation of Preferences, Rights and Limitations of Series DF-1 Convertible Preferred Stock EX-3.1 Exhibit 3.1 INTERSECT ENT, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES DF-1 CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151(g) OF THE DELAWARE GENERAL CORPORATION LAW INTERSECT ENT, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”), does hereby certi
May 11, 2020	EX-4.1	Form of Senior Convertible Note EX-4.1 Exhibit 4.1 THE SECURITIES REPRESENTED BY THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION THEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES REPRESENTED BY THIS NOTE AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION THEREOF MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED E
April 29, 2020	DEF 14A	- DEF 14A DEF 14A 1 d826394ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com
April 24, 2020	CORRESP	COOLEY LLP 3175 HANOVER STREET PALO ALTO, CA 94304-1130 T: (650) 843-5000 F: (650) 849-7400 COOLEY.COM BRETT D. WHITE +1 650 843 5191 [email protected] VIA EDGAR April 24, 2020 United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Paul Fischer Joseph McCann Re: Intersect ENT, Inc. Preliminary Proxy Statement on Schedule 14A Filed April 9, 2020 File No. 001-7900 Ladies and Gentlemen: On behalf of Intersect ENT, Inc. (the ?Comp
April 24, 2020	PRER14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Revised Preliminary Proxy Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 23, 2020	EX-4.6	Form of Preferred Stock Warrant Agreement and Warrant Certificate EX-4.6 Exhibit 4.6 INTERSECT ENT, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF INTERSECT ENT, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this Agreement), dated as of [●], between INTERSECT ENT, INC., a Delaware corporation (the Company), and [●], a [corporation] [national banking association] organized and existin
April 23, 2020	S-3ASR	- S-3ASR S-3ASR Table of Contents As filed with the Securities and Exchange Commission on April 23, 2020 Registration No.
April 23, 2020	EX-4.3	Form of Debt Indenture EX-4.3 Exhibit 4.3 INTERSECT ENT, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8
April 23, 2020	EX-4.5	Form of Common Stock Warrant Agreement and Warrant Certificate EX-4.5 Exhibit 4.5 INTERSECT ENT, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF INTERSECT ENT, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [●], between INTERSECT ENT, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existing under t
April 23, 2020	EX-4.7	Form of Debt Securities Warrant Agreement and Warrant Certificate EX-4.7 Exhibit 4.7 INTERSECT ENT, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF INTERSECT ENT, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [●], between INTERSECT ENT, INC., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] organized and existin
April 13, 2020	EX-99.1	Intersect ENT Announces Preliminary Revenue for First Quarter 2020 and Provides Business Update in Response to COVID-19 Pandemic - Preliminary Unaudited First Quarter 2020 Revenue Expected to be $19.5 to $19.8 Million - - Company Withdraws Full Year EX-99.1 Exhibit 99.1 Intersect ENT Announces Preliminary Revenue for First Quarter 2020 and Provides Business Update in Response to COVID-19 Pandemic - Preliminary Unaudited First Quarter 2020 Revenue Expected to be $19.5 to $19.8 Million - - Company Withdraws Full Year 2020 Guidance - MENLO PARK, Calif. — April 13, 2020 — Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patient
April 13, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission File
April 9, 2020	PRE 14A	XENT / Intersect ENT, Inc. PRE 14A - - PRE 14A PRE 14A 1 d826394dpre14a.htm PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Com
February 27, 2020	S-8	As filed with the Securities and Exchange Commission on February 27, 2020 S-8 1 d885970ds8.htm S-8 As filed with the Securities and Exchange Commission on February 27, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intersect ENT, Inc. (Exact name of Registrant as specified in its charter) Delaware 20-0280837 (State or other jurisdiction of Incorporation o
February 27, 2020	EX-10.26	Amendment to Offer Letter by and between the registrant and David A. Lehman dated as of November 26, 2019 EX-10.26 Exhibit 10.26 November 26, 2019 David A. Lehman [Address] Re: Amendment to Offer Letter Dated February 7, 2016 Dear David: This amendment (the “Amendment”) sets forth certain amended terms to your employment offer letter with Intersect ENT, Inc. (the “Company”) dated February 7, 2016 (the “Offer Letter”) in connection with your promotion to Executive Vice President & General Counsel. This
February 27, 2020	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-
February 27, 2020	EX-10.25	Offer Letter by and between the registrant and Richard A. Meier, dated as of November 26, 2019 EX-10.25 Exhibit 10.25 November 26, 2019 Richard A. Meier Re: Employment Terms Dear Randy: Intersect ENT, Inc. (the “Company”) is pleased to offer you the position of Executive Vice President and Chief Financial Officer on the following terms. You will be responsible for all aspects of the Company’s financial, accounting and investor relations functions. You will report directly to me, as the Comp
February 27, 2020	EX-4.2	Description of the Company’s Common Stock EX-4.2 Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of February 20, 2020, Intersect ENT, Inc. has one class of Common Stock securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Description of the Company’s Common Stock The following description of our Com
February 24, 2020	EX-99.1	Intersect ENT Reports Fourth Quarter and Full Year 2019 Results EX-99.1 Exhibit 99.1 Intersect ENT Reports Fourth Quarter and Full Year 2019 Results MENLO PARK, Calif.—February 24, 2020 — Intersect ENT, Inc. (NASDAQ:XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today reported financial results for the fourth quarter and full year ended December 31, 2019. 2019 was a year of change for Intersect ENT. New company le
February 24, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission F
February 14, 2020	EX-99.1	JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.
February 14, 2020	SC 13G/A	XENT / Intersect ENT, Inc. / PURA VIDA INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 14, 2020	SC 13G/A	XENT / Intersect ENT, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G/A, #1 Passive Investment SC 13G/A 1 p72intersect13ga1.htm SCHEDULE 13G/A, #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Intersect ENT, Inc. (Title of Cla
February 14, 2020	EX-1	Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, $0.
February 14, 2020	SC 13G/A	XENT / Intersect ENT, Inc. / HealthCor Management, L.P. - SC 13G/A Passive Investment SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2)* Intersect ENT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Fili
February 13, 2020	SC 13G/A	XENT / Intersect ENT, Inc. / Flynn James E Passive Investment SC 13G/A 1 e619350sc13ga-intersect.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * Intersect ENT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) December 3
February 11, 2020	SC 13G	XENT / Intersect ENT, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Intersect ENT Inc Title of Class of Securities: Common Stock CUSIP Number: 46071F103 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule
February 5, 2020	SC 13G/A	XENT / Intersect ENT, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) INTERSECT ENT, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 46071F103 (CUSIP Number) DECEMBER 31, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule
February 5, 2020	SC 13G/A	XENT / Intersect ENT, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Intersect ENT Inc (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
January 22, 2020	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fi
January 13, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2020 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fi
January 13, 2020	EX-99.1	Intersect ENT Reports Preliminary Full Year 2019 Revenue EX-99.1 Exhibit 99.1 Intersect ENT Reports Preliminary Full Year 2019 Revenue MENLO PARK, Calif.—(BUSINESS WIRE)—Jan. 13, 2020— Intersect ENT, Inc. (NASDAQ: XENT), a company transforming care for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the full year ended December 31, 2019. Full Year 2019 Preliminary Revenue Preliminary unaudited revenue for
December 5, 2019	EX-10.1	Second Amendment to Lease by and between the registrant, Menlo Prepi I, LLC, and TPI Investors 9, LLC, dated as of December 2, 2019 EX-10.1 Exhibit 10.1 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is dated as of November 22, 2019 (the “Effective Date”) and is among MENLO PREPI I, LLC, a Delaware limited liability company, and TPI INVESTORS 9, LLC, a California limited liability company (collectively, “Lessor”), and INTERSECT ENT, INC., a Delaware corporation (“Lessee”), with respect to th
December 5, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fi
December 4, 2019	CORRESP	XENT / Intersect ENT, Inc. CORRESP - - CORRESP BRETT D. WHITE +1 650 843 5191 [email protected] VIA EDGAR AND FEDEX December 4, 2019 United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Traci Mariner Terence O’Brian Re: Intersect ENT Form 10-K for Fiscal Year Ended December 31, 2018 Filed February 28, 2019 File No. 001-36545 Dear Ms. Mariner and Mr. O’Brian: On
November 27, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 26, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission F
November 22, 2019	EX-1	Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) EX-1 2 ex-1.htm Exhibit 1 Joint Filing Statement Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, $0.001 Par Value, of Intersect ENT, Inc., beneficially owned by them, together with any or all amendments thereto, when and if appropriate.
November 22, 2019	SC 13G	XENT / Intersect ENT, Inc. / PURA VIDA INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 * Intersect ENT, Inc.
November 5, 2019	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36545 INTERSECT ENT, INC. (
November 1, 2019	EX-99.1	Intersect ENT Reports Third Quarter 2019 Results EX-99.1 Exhibit 99.1 Intersect ENT Reports Third Quarter 2019 Results MENLO PARK, Calif.—November 1, 2019— Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2019. Total revenue was $24.1 million for the third quarter of 2019 compared to $24.7 milli
November 1, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fi
August 5, 2019	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-36545 INTERSECT ENT, INC. (Exact
August 5, 2019	EX-10.1	Offer Letter by and between the registrant and Thomas A. West, dated as of June 24, 2019 EX-10.1 Exhibit 10.1 June 24, 2019 Thomas A. West [address] Re: Employment Terms Dear Thomas: Intersect ENT, Inc. (the “Company”) is pleased to offer you the position of President and Chief Executive Officer. Following your Commencement Date you will also be appointed to the Company’s Board of Directors as a member. You will report directly to the Company’s Board of Directors, and you will be base
August 1, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission
August 1, 2019	EX-99.1	Intersect ENT Reports Second Quarter 2019 Results CMS Assigns New J Code for SINUVA and PROPEL, Effective October 1 EX-99.1 Exhibit 99.1 Intersect ENT Reports Second Quarter 2019 Results CMS Assigns New J Code for SINUVA and PROPEL, Effective October 1 MENLO PARK, Calif.—August 1, 2019— Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2019. In addition, the company
July 25, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission F
June 27, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission F
June 10, 2019	SC 13G/A	XENT / Intersect ENT, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Intersect ENT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) May 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul
June 6, 2019	8-K	Submission of Matters to a Vote of Security Holders 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fi
May 10, 2019	SC 13G	XENT / Intersect ENT, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Intersect ENT, Inc. (Title of Class of Securities) Common Stock, Par Value $0.001 Per S
May 10, 2019	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi
May 8, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fil
May 7, 2019	10-Q	Quarterly Report - 10-Q 10-Q 1 d708858d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-365
May 7, 2019	EX-10.1	Processing Agreement by and between the registrant and Isomedix Operations Inc., dated as of February 1, 2019 EX-10.1 [*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Exhibit 10.1 PROCESSING AGREEMENT THIS PROCESSING AGREEMENT (“Agreement”) is made on January 1, 2019 (the “Effective Date”) between Isomedix Operations Inc., including its affiliates, Isomedix Co
May 7, 2019	EX-10.2	Amendment to Offer Letter by and between the registrant and Robert H. Binney, Jr., dated as of January 17, 2019 EX-10.2 Exhibit 10.2 January 16, 2019 Robert Binney Re: Amended and Restated Employment Terms Dear Rob: Intersect ENT, Inc. (the “Company”) is pleased to offer you the position of Chief Commercial Officer on the following terms. These terms shall supersede and replace, in their entirety, the terms set forth in your most recent offer letter from the Company (which was effective June 23, 2011, as am
May 6, 2019	DEFA14A	XENT / Intersect ENT, Inc. DEFA14A DEFA14A DEFA14A 1 d743373ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi
May 6, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d651223d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorpora
May 6, 2019	EX-99.1	Intersect ENT Reports First Quarter 2019 Results EX-99.1 Exhibit 99.1 Intersect ENT Reports First Quarter 2019 Results MENLO PARK, Calif.—May 6, 2019 — Intersect ENT®, Inc. (NASDAQ:XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2019. Total revenue was $26.7 million for the first quarter of 2019 compared to $24.7 million for
April 23, 2019	DEFA14A	XENT / Intersect ENT, Inc. DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 23, 2019	DEF 14A	XENT / Intersect ENT, Inc. DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 28, 2019	S-8	XENT / Intersect ENT, Inc. FORM S-8 Form S-8 As filed with the Securities and Exchange Commission on February 28, 2019 Registration No.
February 28, 2019	EX-10.28	Amendment to Offer Letter by and between the registrant and Susan P. Stimson, dated as of October 26, 2018 EX-10.28 Exhibit 10.28 October 29, 2018 Susan Stimson Re: Amended and Restated Employment Terms Dear Susan: Intersect ENT, Inc. (the “Company”) is pleased to offer you the position of Chief Strategy Officer on the following terms. These terms shall supersede and replace, in their entirety, the terms set forth in your most recent offer letter from the Company (which was effective January 21, 2014)
February 28, 2019	EX-10.23	Amendment to Offer Letter by and between the registrant and Richard E. Kaufman, dated as of October 26, 2018 EX-10.23 Exhibit 10.23 October 26, 2018 Richard Kaufman Re: Amended and Restated Employment Terms Dear Rich: You have advised us of your desire to retire from the Company and to provide us transition assistance as we recruit and hire new executives. We have agreed that you will continue as an employee of the Company until March 31, 2019, unless we mutually agree to an earlier date, or unless you a
February 28, 2019	EX-10.27	Offer Letter by and between the registrant and Christine R. Kowalski, dated as of October 26, 2018 EX-10.27 Exhibit 10.27 October 17, 2018 Christine Kowalski Re: Employment Terms Dear Christine: Intersect ENT, Inc. (the “Company”) is pleased to offer you the position of Chief Operations Officer on the following terms. You will be responsible for the management and oversight of all manufacturing operations and personnel, as well as for all aspects of the supply chain, facilities, quality systems
February 28, 2019	EX-10.42	Analytical Testing Partnership Program 2018-2020 by and between the registrant and Exova Group Limited, dated as of April 26, 2018 EX-10.42 Exhibit 10.42 Exova 2395 Speakman Dr. Mississauga Ontario Canada L5K 1B3 T: + 1 (905) 822-4111 F: + 1 (905) 823-1446 E: [email protected] W: [email protected] Testing. Calibrating. Advising [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securiti
February 28, 2019	10-K	XENT / Intersect ENT, Inc. 10-K (Annual Report) 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 25, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d709098d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of inc
February 25, 2019	EX-99.1	Intersect ENT Reports Fourth Quarter and Full Year 2018 Results ENCORE Clinical Study Completed, Primary Endpoints Met EX-99.1 Exhibit 99.1 Intersect ENT Reports Fourth Quarter and Full Year 2018 Results ENCORE Clinical Study Completed, Primary Endpoints Met MENLO PARK, Calif.—February 25, 2019 — Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and full year ended Decemb
February 15, 2019	SC 13G	XENT / Intersect ENT, Inc. / INTEGRATED CORE STRATEGIES (US) LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INTERSECT ENT, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 46071F103 (CUSIP Number) FEBRUARY 7, 2019 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which
February 14, 2019	EX-99.1	JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.
February 14, 2019	SC 13G/A	XENT / Intersect ENT, Inc. / HealthCor Management, L.P. - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv513196sc13ga.htm SCHEDULE 13G/A SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Intersect ENT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) Decembe
February 12, 2019	SC 13G/A	XENT / Intersect ENT, Inc. / Flynn James E Passive Investment SC 13G/A 1 e618205sc13ga-inersect.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Intersect ENT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) December 31
February 12, 2019	EX-99	JOINT FILING AGREEMENT Invesco Joint Filing Agreement JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) (l) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing of the attached Schedule 13G, and any and all amendments thereto, and expressly authorize Invesco Ltd.
February 12, 2019	SC 13G	XENT / Intersect ENT, Inc. / Invesco Ltd. - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Intersect ENT Inc (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu
February 12, 2019	SC 13G/A	XENT / Intersect ENT, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Intersect ENT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc
February 7, 2019	8-K	Entry into a Material Definitive Agreement FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Comm
February 7, 2019	SC 13G/A	XENT / Intersect ENT, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 18, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Comm
January 18, 2019	EX-10.1	2019 Named Executive Officer Compensation. Exhibit 10.1 Exhibit 10.1 2019 Named Executive Officer Compensation Name Base Salary (Annual Rate) (1) Target Performance Bonus (% of Base Salary) (2) Lisa D. Earnhardt $580,000 80% President and Chief Executive Officer Jeryl L. Hilleman $430,000 50% Chief Financial Officer David A. Lehman $390,000 45% General Counsel (1) Effective January 1, 2019. (2) The actual bonus to be awarded will be at the
January 7, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2019 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission
January 7, 2019	EX-99.2	Forward-Looking Statements Certain statements in this presentation constitute “forward-looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), and Securities Exchange Act of 1934, as amended (“Exchange EX-99.2 Delivering Innovation. Where It’s Needed. January 2019 Exhibit 99.2 Forward-Looking Statements Certain statements in this presentation constitute “forward-looking statements” within the meaning of the Securities Act of 1933, as amended (the “Securities Act”), and Securities Exchange Act of 1934, as amended (“Exchange Act”), including, without limitation, statements regarding our outlook fo
January 7, 2019	EX-99.1	Intersect ENT Reports Preliminary Fourth Quarter and Full Year 2018 Revenue EX-99.1 Exhibit 99.1 Intersect ENT Reports Preliminary Fourth Quarter and Full Year 2018 Revenue MENLO PARK, Calif.—(BUSINESS WIRE)—Jan. 7, 2019—Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2018. Fourth Q
November 5, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2018 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commissio
November 5, 2018	EX-99.1	Intersect ENT Reports Third Quarter 2018 Results EX-99.1 Exhibit 99.1 Intersect ENT Reports Third Quarter 2018 Results MENLO PARK, Calif. — November 5, 2018 — Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2018. Third Quarter Financial Results Total revenue grew to $24.7 million fo
November 5, 2018	10-Q	XENT / Intersect ENT, Inc. 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 29, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2018 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commissio
August 13, 2018	EX-99.1	JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT I JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.
August 13, 2018	SC 13G	XENT / Intersect ENT, Inc. / HealthCor Management, L.P. - SC 13G Passive Investment SC 13G 1 tv500783sc13g.htm SC 13G SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. )* Intersect ENT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) August 1, 2018 (Dat
August 3, 2018	S-8	XENT / Intersect ENT, Inc. S-8 S-8 As filed with the Securities and Exchange Commission on August 3, 2018 Registration No.
August 3, 2018	10-Q	XENT / Intersect ENT, Inc. 10-Q (Quarterly Report) 10-Q 1 d604500d10q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-3654
August 3, 2018	EX-10.2	Amended and Restated 2014 Employee Stock Purchase Plan, as approved by Stockholders’ on June 5, 2018 EX-10.2 Exhibit 10.2 INTERSECT ENT, INC. AMENDED AND RESTATED 2014 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: JULY 7, 2014 APPROVED BY THE STOCKHOLDERS: JULY 10, 2014 IPO DATE/EFFECTIVE DATE: JULY 23, 2014 AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: DECEMBER 13, 2017 AMENDMENT AND RESTATEMENT APPROVED BY THE STOCKHOLDERS: JUNE 5, 2018 1. GENERAL; PURPOSE. (a) The Plan prov
August 3, 2018	SC 13G	XENT / Intersect ENT, Inc. / Flynn James E Passive Investment SC 13G 1 e618211sc13g-inersect.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. ) * Intersect ENT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) August 1, 2018
August 3, 2018	EX-10.1	Amendment to Offer Letter by and between the registrant and Drake R. Parker, dated as of April 3, 2018 EX-10.1 Exhibit 10.1 April 2, 2018 VIA HAND DELIVERY Drake Parker Intersect ENT, Inc. 1555 Adams Drive Menlo Park, CA 94025 Dear Drake: This letter sets forth the substance of the transition and separation agreement (the “Agreement”) that Intersect ENT, Inc. (the “Company”) is offering to you. The terms set forth herein amend and supersede your offer of employment dated July 6, 2017. 1. Transition
August 1, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2018 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission
August 1, 2018	EX-99.1	Intersect ENT Reports Second Quarter 2018 Results EX-99.1 Exhibit 99.1 Intersect ENT Reports Second Quarter 2018 Results MENLO PARK, Calif. – August 1, 2018 – Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the second quarter ended June 30, 2018. On April 1, 2018, the company announced commencement of the commercial laun
June 7, 2018	8-K	Submission of Matters to a Vote of Security Holders Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2018 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commissi
May 3, 2018	10-Q	XENT / Intersect ENT, Inc. 10-Q (Quarterly Report) 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 1, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2018 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commission Fil
May 1, 2018	EX-99.1	Intersect ENT Reports First Quarter 2018 Results EX-99.1 Exhibit 99.1 Intersect ENT Reports First Quarter 2018 Results MENLO PARK, Calif.— May 1, 2018 — Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2018. Recent Business Highlights In April 2018, the company announced U.S. commercial
April 23, 2018	DEFA14A	XENT / Intersect ENT, Inc. DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 23, 2018	DEF 14A	XENT / Intersect ENT, Inc. DEFINITIVE PROXY STATEMENT Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 28, 2018	S-8	XENT / Intersect ENT, Inc. S-8 S-8 As filed with the Securities and Exchange Commission on February 28, 2018 Registration No.
February 28, 2018	10-K	XENT / Intersect ENT, Inc. FORM 10-K (Annual Report) Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 27, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2018 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Com
February 27, 2018	EX-99.1	Intersect ENT Reports Fourth Quarter and Full Year 2017 Results EX-99.1 Exhibit 99.1 Intersect ENT Reports Fourth Quarter and Full Year 2017 Results MENLO PARK, Calif.?February 27, 2018 ? Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and year ended December 31, 2017. Recent Business Highlights ? In December 2017,
February 14, 2018	SC 13G/A	XENT / Intersect ENT, Inc. / Flynn James E Passive Investment SC 13G/A 1 e617671sc13ga-intersect.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) * Intersect ENT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) December 3
February 8, 2018	SC 13G/A	XENT / Intersect ENT, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Intersect ENT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc
January 31, 2018	SC 13G/A	XENT / Intersect ENT, Inc. / U S Venture Partners IX L P - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3)* Intersect ENT, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46071F103 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this St
January 26, 2018	SC 13G/A	XENT / Intersect ENT, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 19, 2018	8-K	XENT / Intersect ENT, Inc. FORM 8-K (Current Report) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2018 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Comm
January 19, 2018	EX-10.1	2018 Compensation Arrangements with Named Executive Officers EX-10.1 Exhibit 10.1 2018 Named Executive Officer Compensation Name Base Salary (Annual Rate) (1) Target Performance Bonus (% of Base Salary) (2) Lisa D. Earnhardt President and Chief Executive Officer $ 556,210 75 % Jeryl L. Hilleman Chief Financial Officer $ 378,000 50 % Gwen R. Carscadden Chief People Officer $ 285,000 35 % Richard E. Kaufman Senior Vice President and Chief Operating Officer $
January 8, 2018	EX-99.1	Intersect ENT Reports Preliminary Q4 and Year 2017 Revenue Full Year Revenue Grew Approximately 22% Year Over Year EX-99.1 Exhibit 99.1 Intersect ENT Reports Preliminary Q4 and Year 2017 Revenue Full Year Revenue Grew Approximately 22% Year Over Year MENLO PARK, Calif.?January 8, 2018?Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported preliminary unaudited revenue for the fourth quarter and year ended Decemb
January 8, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2018 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commi
November 16, 2017	SC 13G	XENT / Intersect ENT, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.
November 6, 2017	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 6, 2017	EX-10.1	Offer Letter by and between the registrant and Drake R. Parker, dated as of July 12, 2017 EX-10.1 Exhibit 10.1 July 6, 2017 Drake Parker Re: Employment Terms Dear Drake: Intersect ENT, Inc. (the “Company”) is pleased to offer you the position of Chief Business Officer on the following terms. You will be responsible for the Company’s global marketing, business development and market access initiatives, strategies and activities. You will report directly to me, as the Company’s CEO, and
November 2, 2017	EX-99.1	Intersect ENT Reports Third Quarter 2017 Results EX-99.1 Exhibit 99.1 Intersect ENT Reports Third Quarter 2017 Results MENLO PARK, Calif.?November 2, 2017 ? Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the third quarter ended September 30, 2017. Third quarter 2017 revenue was $22.3 million, a 21% increase over the th
November 2, 2017	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2017 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Comm
October 10, 2017	8-K	Intersect ENT FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2017 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Commi
October 10, 2017	EX-99.1	Intersect ENT Announces Presentation of Results from RESOLVE II, a Pivotal Phase III Study Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant EX-99.1 Exhibit 99.1 Intersect ENT Announces Presentation of Results from RESOLVE II, a Pivotal Phase III Study Evaluating the Safety and Efficacy of SINUVA?, an Investigational Steroid Releasing Sinus Implant MENLO PARK, Calif. & BARCELONA, Spain ? Oct. 8, 2017 ? Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions,
October 10, 2017	EX-99.2	The role of corticosteroid-eluting stents for the management of recurrent nasal polyposis Robert C. Kern MD George A. Sisson Professor of Otolaryngology Chairman, Department of Otolaryngology-Head and Neck Surgery Northwestern University Feinberg Sch EX-99.2 Exhibit 99.2 The role of corticosteroid-eluting stents for the management of recurrent nasal polyposis Robert C. Kern MD George A. Sisson Professor of Otolaryngology Chairman, Department of Otolaryngology-Head and Neck Surgery Northwestern University Feinberg School of Medicine Chicago, Illinois Disclosures Received research grants from NIH (Core PI) and Intersect ENT (Co-PI) Received cons
September 11, 2017	8-K	Intersect ENT FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2017 Intersect ENT, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36545 20-0280837 (State or other jurisdiction of incorporation) (Com
September 11, 2017	EX-99.2	Study of corticosteroid-eluting implants placed EX-99.2 Exhibit 99.2 Study of corticosteroid-eluting implants placed in-office as an alternative to revision surgery in patients with recurrent sinus obstruction due to polyposis: a meta-analysis J. Pablo Stolovitzky, MD, Atlanta, GA Robert L. Kern, MD, Chicago, IL Joseph K. Han, MD, Norfolk, VA Keith D. Forwith, PhD, MD, Louisville, KY Randall A. Ow, MD, Roseville, CA ndrew Gould, MD, Louisville,
September 11, 2017	EX-99.1	Intersect ENT Announces Presentation of a Meta-Analysis from Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA™, an Investigational Steroid Releasing Sinus Implant EX-99.1 Exhibit 99.1 Intersect ENT Announces Presentation of a Meta-Analysis from Two Randomized Studies Evaluating the Safety and Efficacy of SINUVA?, an Investigational Steroid Releasing Sinus Implant MENLO PARK, Calif. and Chicago ? Sept. 9, 2017 ? Intersect ENT, Inc. (NASDAQ: XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announ
August 4, 2017	EX-10.1	Amendment to Offer Letter by and between the registrant and Richard E. Kaufman, dated as of May 8, 2017 EX-10.1 Exhibit 10.1 VIA HAND DELIVERY May 8, 2017 Richard Kaufman Intersect ENT, Inc. 1555 Adams Drive Menlo Park, CA 94025 Re: Amended Separation Benefits Dear Richard: This letter agreement sets out an amendment (the “Amendment’) to the terms of your employment offer letter with Intersect ENT, Inc. (the “Company’’) dated December 6, 2006, as amended November 18,2013 and January 26, 2015 (collec

XENT / Intersect ENT Inc - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

الإحصائيات الأساسية

SEC Filings

SEC Filings (Chronological Order)